The objective of this study is to investigate the PK, PD, safety, and tolerability of ivosidenib in adult participants with IDH1-mutated malignancies and hepatic impairment (HI)/ renal impairment (RI). Participants will be enrolled into one of 5 groups based on their hepatic or renal function. During the treatment period participants will have study visits on days 1, 4, 8, 15, 22, and 28 of Cycle 1, on days 1 and 15 of Cycle 2 and 3, and on day 1 of each additional cycle. Each cycle is 28 consecutive days of treatment and cycles will be continuous until the end of the study. Approximately 30 days after treatment has ended, a safety follow-up visit will occur. Study visits may include blood tests, ECG, vital signs, and a physical examination.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Maximum observed steady-state concentration (Cmax,ss)
Timeframe: Through day 28 of cycle 1
Area under the concentration time curve from 0 to 24 hours (AUC0-24hr)
Timeframe: Through day 28 of cycle 1
Predose plasma concentration (Ctrough)
Timeframe: Through day 28 of cycle 1
Time to maximum observed concentration (Tmax)
Timeframe: Through day 28 of cycle 1
Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department